Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.55 |
| ▸ | BTK | Q06187 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 9/20 | 0.50 |
| ▸ | LCK | P06239 | 5/20 | 0.50 |
| ▸ | CSF1R | P07333 | 5/20 | 0.50 |
| ▸ | KIT | P10721 | 4/20 | 0.50 |
| ▸ | FLT3 | P36888 | 4/20 | 0.50 |
| ▸ | LYN | P07948 | 4/20 | 0.50 |
| ▸ | SRC | P12931 | 4/20 | 0.50 |
| ▸ | FLT1 | P17948 | 4/20 | 0.50 |
| ▸ | BLK | P51451 | 4/20 | 0.50 |
| ▸ | FLT4 | P35916 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.46 |
| ▸ | GSK3A | P49840 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | PRKACA | P17612 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8401672 | 0.82 | BTK (0.57) | JAK2BTKKDRLCKCSF1R | |
| SCHEMBL6116012 | 0.81 | BTK (0.57) | BTKKDRLCKCSF1RKIT | |
| SCHEMBL8401763 | 0.78 | BTK (0.56) | JAK2BTKKDRLCKCSF1R | |
| SCHEMBL6115425 | 0.78 | BTK (0.67) | BTKKDRLCKCSF1RKIT | |
| SCHEMBL1703256 | 0.77 | BTK (0.67) | JAK2BTKKDRLCKCSF1R | |
| SCHEMBL8401736 | 0.76 | BTK (0.48) | JAK2BTKKDRLCKCSF1R | |
| SCHEMBL6115984 | 0.76 | BTK (0.51) | BTKKDRLCKCSF1RKIT | |
| SCHEMBL6116428 | 0.76 | BTK (0.54) | BTKKDRLCKCSF1RKIT | |
| SCHEMBL29968161 | 0.74 | KDR (0.79) | JAK2KDRLCKCSF1RKIT | |
| SCHEMBL6116270 | 0.74 | BTK (0.55) | JAK2BTKKDRLCKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753428-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
| WO-2005110410-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | JAK2 77/4885BTK 83/4885KDR 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.